Switch theme
Sign up to access all valuation multiples
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
2009
115
LTM Revenue $76.6M
Last FY EBITDA -$66.8M
$63.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Scilex Holding has a last 12-month revenue (LTM) of $76.6M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Scilex Holding achieved revenue of $56.6M and an EBITDA of -$66.8M.
Scilex Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Scilex Holding valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $76.6M | XXX | $56.6M | XXX | XXX | XXX |
| Gross Profit | $55.9M | XXX | $39.9M | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | 71% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$66.8M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -118% | XXX | XXX | XXX |
| EBIT | -$69.2M | XXX | -$92.8M | XXX | XXX | XXX |
| EBIT Margin | -90% | XXX | -164% | XXX | XXX | XXX |
| Net Profit | -$62.2M | XXX | -$72.8M | XXX | XXX | XXX |
| Net Margin | -81% | XXX | -129% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $32.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Scilex Holding's stock price is $5.
Scilex Holding has current market cap of $28.1M, and EV of $63.8M.
See Scilex Holding trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $63.8M | $28.1M | XXX | XXX | XXX | XXX | $-1.96 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Scilex Holding has market cap of $28.1M and EV of $63.8M.
Scilex Holding's trades at 1.1x EV/Revenue multiple, and -1.0x EV/EBITDA.
Equity research analysts estimate Scilex Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Scilex Holding has a P/E ratio of -0.5x.
See valuation multiples for Scilex Holding and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $28.1M | XXX | $28.1M | XXX | XXX | XXX |
| EV (current) | $63.8M | XXX | $63.8M | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1.0x | XXX | XXX | XXX |
| EV/EBIT | -0.9x | XXX | -0.7x | XXX | XXX | XXX |
| EV/Gross Profit | 1.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.5x | XXX | -0.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 3.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialScilex Holding's last 12 month revenue growth is 153%
Scilex Holding's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $1.2M for the same period.
Scilex Holding's rule of 40 is -81% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Scilex Holding's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Scilex Holding and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 153% | XXX | 137% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -118% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -81% | XXX | 35% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 234% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Scilex Holding acquired XXX companies to date.
Last acquisition by Scilex Holding was XXXXXXXX, XXXXX XXXXX XXXXXX . Scilex Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Scilex Holding founded? | Scilex Holding was founded in 2009. |
| Where is Scilex Holding headquartered? | Scilex Holding is headquartered in United States of America. |
| How many employees does Scilex Holding have? | As of today, Scilex Holding has 115 employees. |
| Who is the CEO of Scilex Holding? | Scilex Holding's CEO is Mr. Jaisim Shah. |
| Is Scilex Holding publicy listed? | Yes, Scilex Holding is a public company listed on NAS. |
| What is the stock symbol of Scilex Holding? | Scilex Holding trades under SCLX ticker. |
| When did Scilex Holding go public? | Scilex Holding went public in 2022. |
| Who are competitors of Scilex Holding? | Similar companies to Scilex Holding include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Scilex Holding? | Scilex Holding's current market cap is $28.1M |
| What is the current revenue of Scilex Holding? | Scilex Holding's last 12 months revenue is $76.6M. |
| What is the current revenue growth of Scilex Holding? | Scilex Holding revenue growth (NTM/LTM) is 153%. |
| What is the current EV/Revenue multiple of Scilex Holding? | Current revenue multiple of Scilex Holding is 0.8x. |
| Is Scilex Holding profitable? | Yes, Scilex Holding is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
